Prescribing COX-2 inhibitors

Current situation

  • Prescribing of celecoxib has fallen dramatically in the UK since the withdrawal of rofecoxib from the market.
  • There has been recent concern about the cardiovascular safety of COX-2 inhibitors.

What is the evidence?

  • The APPROVe study led to the withdrawal of rofecoxib because the incidence of cardiovascular events was double with rofecoxib compared to placebo (N Eng J Med 2005; 352: 1,092).
  • The APC trial found that compared to placebo, celecoxib was associated with an excess of cardiovascular events, with a dose-related increase in risk (N Eng J Med 2005; 352: 1,071).
  • In contrast, a pooled analysis of the cardiovascular safety of several COX-2 inhibitors in a high-risk population did not provide any evidence of an increased risk (Arch Intern Med 2005; 165: 181).
  • A recent meta-analysis has shown that COX-2 inhibitors and high-dose traditional NSAIDs are associated with a moderate increased risk of vascular events (BMJ 2006; 332: 1,302–5).
  • A meta-analysis of four trials comparing celecoxib with placebo found that the odds ratio of MI compared to placebo was 2.2 (J R Soc Med 2006; 99: 132).
  • A UK study of primary care patients has shown that there is no evidence that COX-2 inhibitors are more GI protective than NSAIDs (BMJ 2005; 331: 1,310).

Implications for practice

  • Most data suggest that conventional NSAIDs have no impact on the risk of cardiovascular events. Conventional NSAIDs may even be cardioprotective (Br J Cardiol 2005; 12: 387).
  • Paracetamol offers an effective and safe treatment for generalised musculoskeletal pain (Cochrane Database Syst Rev 2006;(1): CD004257).
  • One meta-analysis has shown that the combination of NSAIDs with proton-pump inhibitors seems to be less likely to cause dyspepsia in patients with arthritis than COX-2 inhibitors (Am J Med 2006; 119: 448).

Available guidelines

  • The MHRA recommend avoiding treatment with COX-2 inhibitors in patients with known IHD.
  • The European Medicines Agency (EMEA) has decided that the benefit-risk balance of NSAIDs remains favourable.
  • NICE recommends the use of COX-2 inhibitors for arthritis.

Useful websites

NICE

Medicines and Healthcare Products Regulatory Agency

European Medicines Agency

- Dr Louise Newson is a GP in the West Midlands and author of ‘Hot Topics for MRCGP and General Practitioners’, PasTest 2006

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register

Already registered?

Sign in

Follow Us:

Just published

GP dilemma: What should I do if a parent sends their child with COVID-19 symptoms to school?

GP dilemma: What should I do if a parent sends their child with COVID-19 symptoms to school?

Medical Protection's Dr Clare Devlin offers advice on how GPs should respond to parents...

GPs risk missing out on vital COVID-19 risk assessments, BMA warns

GPs risk missing out on vital COVID-19 risk assessments, BMA warns

GPs risk missing out on COVID-19 risk assessments unless practices are guaranteed...

GPs call for partial suspension of network DES amid heavy workload

GPs call for partial suspension of network DES amid heavy workload

GPs leading primary care networks (PCNs) have called for the partial suspension of...

UK COVID-19 alert level raised as GPs prioritised for testing

UK COVID-19 alert level raised as GPs prioritised for testing

The government has raised the UK's COVID-19 alert level to four amid reports that...

UK on course for 50,000 COVID-19 cases a day by mid-October

UK on course for 50,000 COVID-19 cases a day by mid-October

The UK could see 50,000 COVID-19 cases per day by mid-October, with the epidemic...

Stricter short-term COVID-19 measures needed to avoid second national lockdown, BMA warns

Stricter short-term COVID-19 measures needed to avoid second national lockdown, BMA warns

COVID-19 infection rates will ‘soar’ and the NHS will ‘once again be crippled’ if...